Review Reports
- Kittipat Supchukun 1,
- Teerapong Yata 2 and
- Sayamon Srisuwatanasagul 4,*
- et al.
Reviewer 1: Anonymous Reviewer 2: Filbert Totsingan Reviewer 3: Anonymous
Round 1
Reviewer 1 Report
Comments and Suggestions for AuthorsThe work dedicated to interesting topic “Ethyl Lauroyl Arginate-Integrated Lipid Nanoparticles as a 2
Multifunctional Non-Antibiotic Platform: Sustained Release, Follicular Penetration, and Broad-Spectrum Activity Against Canine Skin Pathogens”
Manuscript no: pharmaceutics-4489296
The manuscript is subject to the following major changes and should not be considered for publication in JDDST until these changes are made.
- Keywords should be changed to be more sounding
- Abstract should be changed to be more concise.
- Section 2.2 please state the source from which these strains were originally isolated to support clinical relevance.
- Section 2.3. Please Include the exact operating homogenizer speed (e.g., rpm) and duration of homogenization step prior to sonication, as these factors affect droplet size.
- Section 2.4. when diluting nanoparticle dispersions in plain deionized water the ionic strength and this affect zeta potential readings. Have authors tried to test low-ionic-strength medium (such as 1 mM NaCl or buffer).
- Figure 4 please change the setting to make spectra in cascade not overlayed.
- Section 2.5. please state which specific formulation was labelled as the "optimal formulation" how size was measured using TEM have authors used software like ImageJ?.
- Section 2.8. Authors should confirm that the saturation solubility of LAE in the PBS/ethanol (95:5) medium is greater than the total drug added to ensure sink conditions were maintained throughout the release process.
- Section 2.8. cationic surfactants readily bind to synthetic membranes, did authors checked whether LAE adsorbs to the dialysis membrane or the nylon syringe filter by performing a preliminary recovery test with LAE solutions of known initial concentration.
- In section 2.9. M. pachydermatis is a non-lipid-dependent Malassezia species, growth and CFU recovery are frequently improved by supplementing Sabouraud Dextrose Agar (SDA) with lipid sources (e.g., 0.5% Tween-80 or olive oil) and incubating at 32–35 °C rather than 37 °C.
- Grammar and spelling mistakes should be checked. The paper should undergo professional language editing before it can be published.
- Please follow journal style for references check ref 3 vs 4
Comments on the Quality of English Language
The English could be improved to more clearly express the research.
Author Response
Please see the attachment
Author Response File:
Author Response.pdf
Reviewer 2 Report
Comments and Suggestions for AuthorsIn this manuscript, the authors developed N-lauryl arginine ethyl ester-integrated lipid-based nanoparticles (LAE-LBNs) and assessed their potential as a multifunctional non-antibiotic topical delivery platform for veterinary dermatological applications. The optimized formulation exhibited excellent physicochemical stability, high encapsulation efficiency, sustained zero-order drug release, broad-spectrum antimicrobial activity against methicillin-resistant and methicillin-susceptible Staphylococcus pseudintermedius and Malassezia pachydermatis, and favorable localization within the superficial skin layers and hair follicles. This study is interesting and will bring a significant contribution to the field. Therefore, I recommend acceptance after the following points have been thoroughly addressed by the authors.
- In eq. 2, is Q0 the initial amount in the release medium or in the formulation?
- what was the pH of LAE-aq solution used in the study? was it measured?
- Throughout the study, the authors compared three systems all with different pH values: LBN nanocarrier (pH 4.2), 5%LAE-LBN (pH 2.4) and LAE-aq (pH???). The main issue I have with these comparisons is the difference in pH. The comparison will make sense at similar pH values. How did the authors rule out the pH effect? Any data available for LAE-LBN vs. pH? What will be the behavior of 5%LAE-LBN at pH 4.2 (same as the blank)?
- Was the ethyl ester fully stable for two months at such acidic pH? Any evidence of hydrolysis (via HPLC)?
Author Response
Please see the attachment.
Author Response File:
Author Response.pdf
Reviewer 3 Report
Comments and Suggestions for AuthorsManuscript ID: pharmaceutics-4489296
Ethyl Lauroyl Arginate-Integrated Lipid Nanoparticles as a Multifunctional Non-Antibiotic Platform: Sustained Release, Follicular Penetration, and Broad-Spectrum Activity Against Canine Skin Pathogens
Kittipat Supchukun, Teerapong Yata, Jakarwan Yostawonkul, Benchaphorn Limcharoen, Sayamon Srisuwatanasagul
The presented work to develop ethyl lauroyl arginate-integrated lipid-based nanoparticles (LAE-LBNs) as a non-antibiotic topical delivery platform capable of providing sustained antimicrobial release, enhanced skin localization, and broad-spectrum activity against major canine skin pathogens. This theme is in the scope of Pharmaceutics. The data obtained have practical significance and may be of interest to researchers working in the field of developing transdermal drug delivery systems. However, I have a number of questions and comments.
First of all, the authors should correctly identify the surfactant they are working with. Judging by the fact that they refer to ethyl lauroyl arginate as a cationic surfactant, and also by the CAS No. 60372-77-2 listed for the compound under study in the experimental section, they are working with ethyl lauroyl arginate hydrochloride. However, this is not stated in the text. The image in Figure 1 also does not allow one to classify this surfactant as cationic.
The in vitro release profiles of aqueous LAE (LAE-Aq) and lipid-loaded LAE raise many questions. The authors do not report any errors in determining the LAE content. In the period up to 24 hours, the LAE concentration values shown are 0, which the authors attribute to the analytical limit of detection. However, there are techniques for concentrating samples and obtaining actual values. The use of any mathematical models for the relationships obtained from three experimental points is unacceptable. The authors should obtain a more reliable LAE release profile with a sufficient number of experimental points and attempt to describe it using traditional mathematical models, such as first-order, Higuchi, and Korsmeyer-Peppas. The zero-order release model typically yields poor results for such processes.
I recommend converting the results from Table 1 into text, as all the values given there are identical. Experimental error should be noted. It would be useful to provide and compare the MBC or MFC of LAE-LBNs for the indicated strains with those of commercial antibiotics used.
The results described in Section 3.2, Physicochemical Stability of LAE-LBNs, would be more clearly presented in a table, indicating the statistical deviations of the obtained values. I recommend including Figure 2 in the SI.
In my opinion, the section on Fourier-transform infrared spectroscopy is uninformative.
The reference list does not include the email addresses of the cited articles, making it difficult to review and access the submitted manuscript.
Taking into account the above, I believe that manuscript needs major revision before it can be recommended for publication.
Author Response
Please see the attachment.
Author Response File:
Author Response.pdf
Round 2
Reviewer 1 Report
Comments and Suggestions for AuthorsThis is to confirm that the manuscript is accepted for publication
Comments on the Quality of English LanguageThe English could be improved to more clearly express the research.
Reviewer 2 Report
Comments and Suggestions for AuthorsThe auhors' response to my comments/concerns is satisfactory. Therefore, I recommend acceptance in its current form.
Reviewer 3 Report
Comments and Suggestions for AuthorsAuthors took into account the comments of the reviewer and made corrections to the text of the manuscript. In this form, it can be recommended for publication.